Adult Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes.
The study will last about 59 weeks and may include up to 22 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participant must have type 2 diabetes mellitus (T2DM)
-Participant must be on stable treatment dose of metformin, with or without an SGLT-2 inhibitor
-Participant must be of stable weight
-Participant must not have type 1 diabetes mellitus (T1DM)
-Participant must not have pancreatitis
-Participant must not have disorders with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
-Participant must not have acute or chronic hepatitis or symptoms of any other liver disease
-Participant must not have had a heart attack stroke, or hospitalization for congestive heart failure in the past 2 months
-Participant must not have been taking weight loss drugs including over-the-counter medications during the last 3 months